![Patricia Allen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patricia Allen
Direktor/Vorstandsmitglied bei
Inversago Pharma, Inc.
Vermögen: 365 424 $ am 31.05.2026
Profil
Patricia L.
Allen is currently Director at Anokion SA since 2020, Director at Kanyos Bio, Inc., Independent Director at Inversago Pharma, Inc., Non-Executive Director at SwanBio Therapeutics, Inc. since 2020, and Independent Director at Zenas BioPharma, Inc. since 2024.
Former roles include Finance Director at Alkermes, Inc. from 1992 to 2004, Director at Yumanity, Inc. from 2019 to 2020, Independent Director at Deciphera Pharmaceuticals, Inc. from 2016 to 2024, Independent Director at Yumanity Therapeutics, Inc. from 2020 to 2022, CFO, Treasurer & Principal Accounting Officer at Zafgen, Inc. from 2013 to 2020, Auditor at Deloitte & Touche LLP, Chief Financial Officer, Treasurer & VP at Alnylam Pharmaceuticals, Inc. in 2010, and Chief Financial Officer at Vividion Therapeutics, Inc. from 2021 to 2024.
Education includes undergraduate studies at Bryant University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0.03% | 15.06.2026 | 19’860 ( 0.03% ) | 365 424 $ | 31.05.2026 |
Aktive Positionen von Patricia Allen
| Unternehmen | Position | Beginn |
|---|---|---|
Inversago Pharma, Inc.
 Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops CB1 receptor based therapies for obesity, diabetes and complication treatment | Direktor/Vorstandsmitglied | - |
Anokion SA
 Anokion SA BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies for antigen-specific immune tolerance | Direktor/Vorstandsmitglied | 29.09.2020 |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage gene therapy company that develops treatments for neurological disorders | Direktor/Vorstandsmitglied | 20.11.2020 |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for type 1 diabetes | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Patricia Allen
| Unternehmen | Position | Ende |
|---|---|---|
| DECIPHERA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 11.06.2024 |
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology research company which develops precision therapeutics for cancers and immune disorders | Finanzdirektor/CFO | 01.01.2024 |
| YUMANITY THERAPEUTICS | Direktor/Vorstandsmitglied | 01.12.2022 |
Yumanity, Inc.
 Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Provides transforming drug discovery for neurodegenerative diseases services | Direktor/Vorstandsmitglied | 22.12.2020 |
| LARIMAR THERAPEUTICS, INC. | Finanzdirektor/CFO | 01.05.2020 |
Ausbildung von Patricia Allen
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
56
Beziehungen ersten Grades
13
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 13 |
|---|---|
Alkermes, Inc.
 Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and develops pharmaceutical products | Health Technology |
Zafgen, Inc.
 Zafgen, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company | Health Technology |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Provides auditing, financial advisory and tax consulting services | Commercial Services |
Alnylam Pharmaceuticals, Inc.
 Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Bryant University
 Bryant University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Anokion SA
Anokion SA BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies for antigen-specific immune tolerance | Health Technology |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for type 1 diabetes | Health Technology |
Yumanity, Inc.
Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Provides transforming drug discovery for neurodegenerative diseases services | Health Technology |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology research company which develops precision therapeutics for cancers and immune disorders | Health Technology |
Deciphera Pharmaceuticals, Inc.
 Deciphera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel drug candidates to improve the lives of cancer patients | Health Technology |
Inversago Pharma, Inc.
Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops CB1 receptor based therapies for obesity, diabetes and complication treatment | Health Technology |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage gene therapy company that develops treatments for neurological disorders | Health Technology |
Yumanity Therapeutics, Inc.
 Yumanity Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
